Ciocia Annagiulia, Mestre-Farràs Neus, Vicent-Nacht Ignacio, Guitart Tanit, Gebauer Fátima
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr Aiguader 88, Barcelona 08003, Spain.
Universitat Pompeu Fabra (UPF), Dr Aiguader 88, Barcelona, Spain.
NAR Cancer. 2024 Apr 10;6(2):zcae014. doi: 10.1093/narcan/zcae014. eCollection 2024 Jun.
RNA-binding proteins (RBPs) have garnered significant attention in the field of cancer due to their ability to modulate diverse tumor traits. Once considered untargetable, RBPs have sparked renewed interest in drug development, particularly in the context of RNA-binding modulators of translation. This review focuses on one such modulator, the protein CSDE1, and its pivotal role in regulating cancer hallmarks. We discuss context-specific functions of CSDE1 in tumor development, its mechanisms of action, and highlight features that support its role as a molecular adaptor. Additionally, we discuss the regulation of CSDE1 itself and its potential value as biomarker and therapeutic target.
RNA结合蛋白(RBPs)因其能够调节多种肿瘤特征而在癌症领域备受关注。RBPs曾被认为是不可成药的靶点,如今却引发了药物研发领域的新兴趣,特别是在翻译的RNA结合调节剂方面。本综述聚焦于一种这样的调节剂——蛋白CSDE1,及其在调控癌症特征中的关键作用。我们讨论了CSDE1在肿瘤发展中的特定背景功能、其作用机制,并强调了支持其作为分子衔接子作用的特征。此外,我们还讨论了CSDE1自身的调控及其作为生物标志物和治疗靶点的潜在价值。